Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine | Zendy

Rada Savic | Zendy; Prasanna Jagannathan | Zendy; Richard Kajubi | Zendy; Liusheng Huang | Zendy; Nan Zhang | Zendy; Moses Were | Zendy; Abel Kakuru | Zendy; Mary Muhindo | Zendy; Norah Mwebaza | Zendy; Erika Wallender | Zendy; Tamara D. Clark | Zendy; Bishop Opira | Zendy; Moses R. Kamya | Zendy; Diane V. Havlir | Zendy; Philip J. Rosenthal | Zendy; Grant Dorsey | Zendy; Francesca Aweeka | Zendy

Open Access

Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine

Author(s) -

Rada Savic,

Prasanna Jagannathan,

Richard Kajubi,

Liusheng Huang,

Nan Zhang,

Moses Were,

Abel Kakuru,

Mary Muhindo,

Norah Mwebaza,

Erika Wallender,

Tamara D. Clark,

Bishop Opira,

Moses R. Kamya,

Diane V. Havlir,

Philip J. Rosenthal,

Grant Dorsey,

Francesca Aweeka

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy218

Subject(s) - piperaquine , medicine , dihydroartemisinin , pregnancy , malaria , dosing , pharmacokinetics , pharmacology , adverse effect , parasitemia , dose , plasmodium falciparum , artemisinin , immunology , biology , genetics

Dihydroartemisinin-piperaquine (DHA-PQ) is highly efficacious as intermittent preventive therapy for malaria during pregnancy (IPTp). Determining associations between piperaquine (PQ) exposure, malaria risk, and adverse birth outcomes informs optimal dosing strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research